Selected article for: "body temperature and control group"
Author: JamaliMoghadamSiahkali, Saeidreza; Zarezade, Besharat; Koolaji, Sogol; SeyedAlinaghi, SeyedAhmad; Zendehdel, Abolfazl; Tabarestani, Mohammad; Sekhavati Moghadam, Ehsan; Abbasian, Ladan; Dehghan Manshadi, Seyed Ali; Salehi, Mohamadreza; Hasannezhad, Malihe; Ghaderkhani, Sara; Meidani, Mohsen; Salahshour, Faeze; Jafari, Fatemeh; Manafi, Navid; Ghiasvand, Fereshteh
Title: Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial
  • Cord-id: xqqxtaqb
  • Document date: 2021_2_11
    • ID: xqqxtaqb
    Snippet: BACKGROUND: Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. METHODS: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The
    Document: BACKGROUND: Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. METHODS: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. RESULTS: There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO(2)) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO(2) levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. CONCLUSIONS: We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and admission deteriorate: 1
    • acute ards respiratory distress syndrome and admission mechanical ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and admission median length: 1
    • acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and low efficacy: 1, 2
    • acute ards respiratory distress syndrome and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission day and long duration: 1
    • admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • admission day and lung infection: 1, 2, 3, 4
    • admission mechanical ventilation and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • admission mechanical ventilation and low efficacy: 1
    • admission mechanical ventilation and lung infection: 1, 2, 3, 4
    • admission time and long duration: 1
    • admission time and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission time and low efficacy: 1
    • admission time and lung infection: 1, 2, 3, 4, 5
    • lopinavir ritonavir and low efficacy: 1, 2